{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T10:32:47Z","timestamp":1767177167104,"version":"build-2238731810"},"reference-count":43,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2002,2]]},"abstract":"<jats:p>\n                    PURPOSE: To investigate the activity of a novel dioxolane\n                    <jats:sc>l<\/jats:sc>\n                    -nucleoside analog, troxacitabine (\n                    <jats:sc>l<\/jats:sc>\n                    -(\u2212)-OddC, BCH-4556), in patients with refractory leukemia.\n                  <\/jats:p>\n                  <jats:p>\n                    PATIENTS AND METHODS: Study participants were patients with refractory or relapsed acute myeloid (AML) or lymphocytic (ALL) leukemia, myelodysplastic syndromes (MDS), or chronic myelogenous leukemia in blastic phase (CML-BP). Troxacitabine was provided as an intravenous infusion for more than 30 minutes daily for 5 days at a dose of 8.0 mg\/m\n                    <jats:sup>2<\/jats:sup>\n                    \/d (40 mg\/m\n                    <jats:sup>2<\/jats:sup>\n                    per course). Courses were given every 3 to 4 weeks according to antileukemic efficacy.\n                  <\/jats:p>\n                  <jats:p>RESULTS: Forty-two patients (AML, 18 patients; MDS, one patient; ALL, six patients; CML-BP, 17 patients) were treated. Median age was 51 years (range, 23 to 80 years); 22 patients were male. Stomatitis was the most significant adverse event, with three patients (7%) and two patients (5%), respectively, experiencing grade 3 or 4 toxicity. Ten patients (24%) had grade 3 hand-foot syndrome, and two patients (5%) had grade 3 skin rash. One patient (2%) had grade 3 fatigue and anorexia. Marrow hypoplasia occurred between days 14 and 28 in 12 (75%) of 16 assessable patients with AML. Two complete remissions and one partial remission (18%) were observed in 16 assessable patients with AML. None of six patients with ALL responded. Six (37%) of 16 assessable patients with CML-BP experienced a return to chronic-phase disease.<\/jats:p>\n                  <jats:p>CONCLUSION: Troxacitabine has significant antileukemic activity in patients with AML and CML-BP.<\/jats:p>","DOI":"10.1200\/jco.2002.20.3.656","type":"journal-article","created":{"date-parts":[[2017,2,24]],"date-time":"2017-02-24T04:14:58Z","timestamp":1487909698000},"page":"656-664","source":"Crossref","is-referenced-by-count":64,"title":["Phase II Study of Troxacitabine, a Novel Dioxolane Nucleoside Analog, in Patients With Refractory Leukemia"],"prefix":"10.1200","volume":"20","author":[{"given":"Francis J.","family":"Giles","sequence":"first","affiliation":[{"name":"From the Department of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston, TX; Johns Hopkins Oncology Center, Baltimore, MD; and Suire BioChem Inc, Laval, Quebec, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillermo","family":"Garcia-Manero","sequence":"additional","affiliation":[{"name":"From the Department of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston, TX; Johns Hopkins Oncology Center, Baltimore, MD; and Suire BioChem Inc, Laval, Quebec, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge E.","family":"Cortes","sequence":"additional","affiliation":[{"name":"From the Department of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston, TX; Johns Hopkins Oncology Center, Baltimore, MD; and Suire BioChem Inc, Laval, Quebec, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharyn D.","family":"Baker","sequence":"additional","affiliation":[{"name":"From the Department of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston, TX; Johns Hopkins Oncology Center, Baltimore, MD; and Suire BioChem Inc, Laval, Quebec, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carol B.","family":"Miller","sequence":"additional","affiliation":[{"name":"From the Department of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston, TX; Johns Hopkins Oncology Center, Baltimore, MD; and Suire BioChem Inc, Laval, Quebec, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan M.","family":"O'Brien","sequence":"additional","affiliation":[{"name":"From the Department of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston, TX; Johns Hopkins Oncology Center, Baltimore, MD; and Suire BioChem Inc, Laval, Quebec, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah A.","family":"Thomas","sequence":"additional","affiliation":[{"name":"From the Department of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston, TX; Johns Hopkins Oncology Center, Baltimore, MD; and Suire BioChem Inc, Laval, Quebec, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Andreeff","sequence":"additional","affiliation":[{"name":"From the Department of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston, TX; Johns Hopkins Oncology Center, Baltimore, MD; and Suire BioChem Inc, Laval, Quebec, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carol","family":"Bivins","sequence":"additional","affiliation":[{"name":"From the Department of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston, TX; Johns Hopkins Oncology Center, Baltimore, MD; and Suire BioChem Inc, Laval, Quebec, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacques","family":"Jolivet","sequence":"additional","affiliation":[{"name":"From the Department of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston, TX; Johns Hopkins Oncology Center, Baltimore, MD; and Suire BioChem Inc, Laval, Quebec, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hagop M.","family":"Kantarjian","sequence":"additional","affiliation":[{"name":"From the Department of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston, TX; Johns Hopkins Oncology Center, Baltimore, MD; and Suire BioChem Inc, Laval, Quebec, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"233","reference":[{"key":"e_1_3_1_1_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V93.8.2478"},{"key":"e_1_3_1_2_2","first-page":"79","volume":"5","year":"1994","unstructured":"Keating MJ, McLaughlin P, Plunkett W, et al: Fludarabine: Present status and future developments in chronic lymphocytic leukemia and lymphoma. Ann Oncol 5:: 79,1994-83,","journal-title":"Ann Oncol"},{"key":"e_1_3_1_3_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V87.1.256.256"},{"key":"e_1_3_1_4_2","first-page":"1563","volume":"10","year":"1996","unstructured":"Kornblau SM, Gandhi V, Andreeff HM, et al: Clinical and laboratory studies of 2-chlorodeoxyadenosine \u00b1 cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults. Leukemia 10:: 1563,1996-1569,","journal-title":"Leukemia"},{"key":"e_1_3_1_5_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm00001a001"},{"key":"e_1_3_1_6_2","doi-asserted-by":"publisher","DOI":"10.1006\/bbrc.1996.1181"},{"key":"e_1_3_1_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/0166-3542(95)92835-B"},{"key":"e_1_3_1_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.36.4.733"},{"key":"e_1_3_1_9_2","first-page":"3008","volume":"55","year":"1995","unstructured":"Grove KL, Guo X, Liu SH, et al: Anticancer activity of beta--dioxolane-cytidine, a novel nucleoside analogue with the unnatural configuration. Cancer Res 55:: 3008,1995-3011, l l","journal-title":"Cancer Res"},{"key":"e_1_3_1_10_2","first-page":"4187","volume":"56","year":"1996","unstructured":"Grove KL, Cheng YC: Uptake and metabolism of the new anticancer compound beta--(\u2212)-dioxolane-cytidine in human prostate carcinoma DU-145 cells. Cancer Res 56:: 4187,1996-4191, l","journal-title":"Cancer Res"},{"key":"e_1_3_1_11_2","first-page":"4803","volume":"57","year":"1997","unstructured":"Kadhim SA, Bowlin TL, Waud WR, et al: Potent antitumor activity of a novel nucleoside analogue, BCH-4556 (beta--dioxolane-cytidine), in human renal cell carcinoma xenograft tumor models. Cancer Res 57:: 4803,1997-4810, l","journal-title":"Cancer Res"},{"key":"e_1_3_1_12_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008387019062"},{"key":"e_1_3_1_13_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.3.762"},{"key":"e_1_3_1_14_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.270.39.23055"},{"key":"e_1_3_1_15_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M004082200"},{"key":"e_1_3_1_16_2","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/S0026-895X(24)26517-2","volume":"57","year":"2000","unstructured":"Pelicano H, Kukhanova M, Cheng YC: Excision of beta-- and beta--nucleotide analogs from DNA by the human cytosolic 3\u2032- to-5\u2032 exonuclease. Mol Pharmacol 57:: 1051,2000-1055, d l","journal-title":"Mol Pharmacol"},{"key":"e_1_3_1_17_2","doi-asserted-by":"publisher","DOI":"10.1080\/15257770008033019"},{"key":"e_1_3_1_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(95)00205-E"},{"key":"e_1_3_1_19_2","doi-asserted-by":"crossref","first-page":"23234","DOI":"10.1016\/S0021-9258(19)49454-4","volume":"268","year":"1993","unstructured":"Skalski V, Chang CN, Dutschman G, et al: The biochemical basis for the differential anti-human immunodeficiency virus activity of two enantiomers of 2\u2032,3\u2032-dideoxy-3\u2032-thiacytidine. J Biol Chem 268:: 23234,1993-23238, cis","journal-title":"J Biol Chem"},{"key":"e_1_3_1_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02738118"},{"key":"e_1_3_1_21_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.274.28.19655"},{"key":"e_1_3_1_22_2","doi-asserted-by":"crossref","first-page":"16357","DOI":"10.1016\/S0021-9258(17)34015-2","volume":"269","year":"1994","unstructured":"Perrino FW, Miller H, Ealey KA: Identification of a 3\u2032\u21925\u2032-exonuclease that removes cytosine arabinoside monophosphate from 3\u2032 termini of DNA. J Biol Chem 269:: 16357,1994-16363,","journal-title":"J Biol Chem"},{"key":"e_1_3_1_23_2","first-page":"761","volume":"4","year":"1990","unstructured":"Chiba P, Tihan T, Szekeres T, et al: Concordant changes of pyrimidine metabolism in blasts of two cases of acute myeloid leukemia after repeated treatment with ara-C in vivo. Leukemia 4:: 761,1990-765,","journal-title":"Leukemia"},{"key":"e_1_3_1_24_2","doi-asserted-by":"publisher","DOI":"10.1042\/cs0600191"},{"key":"e_1_3_1_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0145-2126(99)00128-9"},{"key":"e_1_3_1_26_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428199809059245"},{"key":"e_1_3_1_27_2","first-page":"197","volume":"72","year":"1998","unstructured":"Grant S: Ara-C: Cellular and molecular pharmacology. Adv Cancer Res 72:: 197,1998-233,","journal-title":"Adv Cancer Res"},{"key":"e_1_3_1_28_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1987.5.7.1007"},{"key":"e_1_3_1_29_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.5.1504"},{"key":"e_1_3_1_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19991001)86:7<1203::AID-CNCR15>3.0.CO;2-3"},{"key":"e_1_3_1_31_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19991001)86:7<1216::AID-CNCR17>3.0.CO;2-O"},{"key":"e_1_3_1_32_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.3.547"},{"key":"e_1_3_1_33_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19991215)86:12<2632::AID-CNCR7>3.0.CO;2-A"},{"key":"e_1_3_1_34_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2400796"},{"key":"e_1_3_1_35_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428199909058478"},{"key":"e_1_3_1_36_2","first-page":"2377","volume":"3","year":"1997","unstructured":"Beran M, Jeha S, O\u2019Brien S, et al: Tallimustine, an effective antileukemic agent in a severe combined immunodeficient mouse model of adult myelogenous leukemia, induces remissions in a phase I study. Clin Cancer Res 3:: 2377,1997-2384,","journal-title":"Clin Cancer Res"},{"key":"e_1_3_1_37_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.20.3513"},{"key":"e_1_3_1_38_2","first-page":"26","volume":"35","year":"1998","unstructured":"Beran M, Kantarjian H: Topotecan in the treatment of hematologic malignancies. Semin Hematol 35:: 26,1998-31,","journal-title":"Semin Hematol"},{"key":"e_1_3_1_39_2","first-page":"396","volume":"10","year":"1996","unstructured":"Kantarjian HM, Beran M, O\u2019Brien S, et al: Evaluation of CI-973, a platinum analogue, in refractory or relapsed acute leukemia. Leukemia 10:: 396,1996-401,","journal-title":"Leukemia"},{"key":"e_1_3_1_40_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200104053441401"},{"key":"e_1_3_1_41_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V94.1.368.413a47_368_371"},{"key":"e_1_3_1_42_2","first-page":"697a,","volume":"94","year":"1999","unstructured":"Druker BJ, Kantarjian H, Sawyers C, et al: Activity of an abl specific tyrosine kinase inhibitor in patients with bcr-abl positive acute leukemias, including chronic myelogenous leukemia in blast crisis. Blood 94:: 697a,,1999 (abstr)","journal-title":"Blood"},{"key":"e_1_3_1_43_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200104053441402"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2002.20.3.656","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T13:50:06Z","timestamp":1749995406000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2002.20.3.656"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,2]]},"references-count":43,"aliases":["10.1200\/jco.20.3.656"],"journal-issue":{"issue":"3","published-print":{"date-parts":[[2002,2]]}},"alternative-id":["10.1200\/JCO.2002.20.3.656"],"URL":"https:\/\/doi.org\/10.1200\/jco.2002.20.3.656","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,2]]}}}